How to Get Tresiba in Nevada: Prescriptions, Telehealth, and Pharmacy Access

What Is Tresiba and Why Do Nevada Patients Request It

Tresiba is the brand name for insulin degludec, an ultra-long-acting basal insulin with a half-life exceeding 25 hours and a duration of action beyond 42 hours. Its flat peakless profile makes day-to-day glucose control more predictable than older basal insulins for many patients.

Novo Nordisk received FDA approval for insulin degludec in September 2015. The approval covered both type 1 and type 2 diabetes in adults, with the pediatric indication (age 1 and older) added later. The full prescribing information is available on the FDA's accessdata portal at https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. [1]

The half-life of 25 hours allows insulin degludec to form soluble multi-hexamers under the skin, producing a depot that releases insulin slowly over more than 42 hours. [2] Because the steady-state pharmacokinetic profile is exceptionally flat, the American Diabetes Association's 2024 Standards of Medical Care note that ultra-long-acting analogs "offer reduced within-patient variability compared with NPH and insulin glargine U-100." [3]

Nevada's growing population in Las Vegas, Reno, Henderson, and North Las Vegas includes a substantial cohort of patients with diabetes seeking access to newer basal insulin options. Telehealth has widened access considerably since 2020, and Nevada's telehealth statutes (NRS 629.515 et seq.) allow prescribing of non-controlled substances via synchronous audio-video encounter without requiring a prior in-person visit. [4]

How to Get a Tresiba Prescription in Nevada

Any Nevada-licensed prescriber who has established a valid provider-patient relationship may write a Tresiba prescription. The relationship may be formed via telehealth under Nevada law, provided the encounter is a live synchronous audio-video session.

Step 1. Choose your prescriber pathway. You can see a primary care physician, endocrinologist, or internist in person, or use a telehealth platform licensed in Nevada. Nurse practitioners with full prescriptive authority and physician assistants with a supervising physician agreement may also prescribe insulin degludec in Nevada.

Step 2. Gather your baseline labs. Most prescribers will want a recent hemoglobin A1C (within 90 days), a fasting glucose, a basic metabolic panel to assess renal function, and a body weight. Patients with type 1 diabetes may also need a C-peptide and GAD-65 antibody result if the diagnosis has not been formally confirmed. [5]

Step 3. Complete the clinical encounter. Expect the provider to review your current insulin regimen, calculate a starting degludec dose (typically 80% of your current total daily basal insulin dose when switching from another basal), and document the medical necessity justification needed for prior authorization. [6]

Step 4. Submit to your pharmacy or mail-order service. Your prescriber sends the Rx electronically. Most retail pharmacies in Nevada stock Tresiba FlexTouch pens (100 units/mL and 200 units/mL), though inventory varies. Mail-order pharmacies affiliated with your insurance plan often provide a 90-day supply at lower cost-sharing.

The entire process from initial telehealth visit to receiving the pen at your door takes 3 to 7 business days when prior authorization is processed without dispute, and 10 to 21 business days when a PA appeal is required.

Telehealth Providers in Nevada Prescribing Tresiba

Telehealth prescribing of insulin degludec is fully legal in Nevada for providers who hold an active Nevada medical license or who have registered under Nevada's telehealth reciprocity framework. [4]

Several national telehealth platforms now serve Nevada patients with diabetes management. When evaluating a platform, confirm that the prescribing clinician holds either a Nevada medical license or a telehealth registration with the Nevada State Board of Medical Examiners, that the platform uses a synchronous video encounter (not asynchronous questionnaire only), and that the platform can submit a prior authorization on your behalf if your insurer requires one.

Telehealth endocrinology consultations have been shown to produce glycemic outcomes comparable to in-person care. A 2021 systematic review published in JMIR Diabetes (N=2,847 participants across 14 randomized trials) found that telehealth diabetes management reduced A1C by a mean of 0.44 percentage points more than usual care over 6 to 12 months. [7] That effect size is modest but clinically meaningful given that most patients in the trials were already on active treatment.

Nevada's rural counties, including Elko, Humboldt, and Nye, have limited endocrinology presence. Telehealth may be the only realistic path to a Tresiba prescription for patients in those areas who cannot travel to Reno or Las Vegas. The Nevada Office of Rural Health lists federally qualified health centers in 14 counties that can provide face-to-face diabetes care when telehealth is not accessible. [8]

Nevada Insurance Coverage and Prior Authorization for Tresiba

Nevada Medicaid (Medicaid Managed Care and the fee-for-service program) does not cover Tresiba for type 1 or type 2 diabetes as of mid-2025. Patients covered by Nevada Medicaid should ask their provider about covered alternatives such as insulin glargine (Basaglar, Lantus, or Semglee) or insulin detemir before pursuing a prior authorization exception. [9]

Commercial insurance plans operating in Nevada, including Anthem BCBS Nevada, Aetna, UnitedHealthcare, and Centene-affiliated plans sold on the Nevada Health Link exchange, typically place Tresiba on Tier 3 or Tier 4 and require prior authorization. A standard PA submission includes:

• Current A1C (most plans accept results within the past 6 months)
• Documentation of an adequate trial (typically 90 days) of a preferred formulary basal insulin that resulted in inadequate glycemic control or an adverse effect
• C-peptide level for type 1 diabetes confirmation (some plans require <0.6 ng/mL)
• Letter of medical necessity from the prescribing clinician

The ADA's 2024 Standards of Medical Care state: "Prior authorization requirements and non-medical switching policies can adversely affect glycemic control and patient safety and should be minimized." [3] That guidance gives prescribers a published reference to cite when arguing for PA approval.

If the initial PA is denied, Nevada law (NRS 689B.255) gives patients the right to an expedited external appeal within 72 hours for urgent medical circumstances and a standard external appeal within 30 days. [10] Insulin-dependent diabetes generally qualifies as urgent when a patient has no remaining supply.

The DEVOTE Trial: Why Providers Choose Tresiba

The DEVOTE trial enrolled 7,637 patients with type 2 diabetes at high cardiovascular risk and compared insulin degludec U-100 with insulin glargine U-100 over a median follow-up of 2 years. Published in the New England Journal of Medicine in 2017, DEVOTE demonstrated non-inferiority for the primary composite endpoint (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke): 8.5% vs. 9.3% MACE rate (HR 0.91; 95% CI 0.78 to 1.06; P<0.001 for non-inferiority). [11]

DEVOTE also showed a significant reduction in severe hypoglycemia with degludec. The rate of severe hypoglycemic episodes was 4.9 per 100 patient-years with degludec versus 6.6 per 100 patient-years with glargine U-100, a 40% lower rate (rate ratio 0.60; 95% CI 0.48 to 0.76; P<0.001). [11] For Nevada patients who drive long distances or work in physically demanding industries, that hypoglycemia difference carries practical weight.

A secondary pharmacokinetic analysis of DEVOTE data published in Diabetes Care confirmed that within-patient day-to-day variability in the glucose-lowering effect was 4-fold lower with degludec than with glargine U-100. [12] Lower variability means fewer unpredictable glucose swings.

Dosing, Titration, and Administration Basics

Tresiba is available as a FlexTouch pen in two concentrations: 100 units/mL (U-100) and 200 units/mL (U-200, for patients requiring more than 20 units per day). The U-200 pen delivers each dose in half the injection volume of U-100.

Typical starting doses are:

• Insulin-naive type 2 diabetes: 10 units once daily, titrated upward by 2 units every 3 days until fasting glucose consistently reaches target (80 to 130 mg/dL per ADA 2024 guidelines). [3]
• Switching from another basal insulin (type 2): Unit-for-unit conversion from insulin glargine or detemir, then titrate as needed.
• Type 1 diabetes: Degludec replaces the current basal dose; most protocols start at 80% of the prior basal dose and titrate to fasting glucose target to reduce hypoglycemia risk during the transition. [6]

Tresiba may be injected at any time of day, but consistency within a roughly 8-hour window day-to-day is recommended. The FDA label permits shifting the injection time by up to 8 hours when the patient's schedule changes. [1] That flexibility is one of the main clinical advantages over insulin glargine U-300 (Toujeo), which carries a similar but slightly narrower dosing-window guidance.

Injection sites include the thigh, upper arm, or abdomen. Rotate sites within each region to prevent lipohypertrophy, which reduces insulin absorption. A 2022 study in Diabetes Technology and Therapeutics (N=227) found that patients injecting into lipohypertrophic tissue required on average 14% higher total daily doses to achieve equivalent glycemic control. [13]

503A Pharmacies in Nevada and Insulin Degludec

503A pharmacies are state-licensed compounding pharmacies regulated under federal FDCA Section 503A and Nevada Board of Pharmacy rules. They compound medications for individual patients based on a valid prescription and are not permitted to compound copies of commercially available drugs without a specific documented patient need (for example, an allergy to a commercial excipient).

Because insulin degludec is a commercially available, FDA-approved drug, a Nevada 503A pharmacy may compound it only when the patient has a documented reason the commercial product is unsuitable. In practice, this means most Nevada patients obtain the commercially manufactured Tresiba FlexTouch pen rather than a compounded preparation. [14]

503B outsourcing facilities (which can produce larger batches without individual patient prescriptions) are not authorized to compound insulin degludec under FDA's current bulk drug substance list. [15] Patients seeing advertisements for "compounded Tresiba" should verify the pharmacy's 503A vs. 503B status and the documented medical necessity on file before accepting a compounded product.

Nevada's Board of Pharmacy maintains an online license verification tool at bop.nv.gov where patients can confirm a pharmacy's active licensure and compounding registration. [16]

Transferring an Existing Tresiba Prescription to Nevada

Moving to Nevada with an active Tresiba prescription from another state is straightforward under federal law: a pharmacist in Nevada may transfer a prescription for a non-controlled substance from an out-of-state pharmacy one time, provided the original prescription has remaining refills. [17]

If the original prescription has no remaining refills, you need a new prescription from a Nevada-licensed provider. A telehealth visit is the fastest path: most platforms can complete the intake and issue a new prescription within 24 to 48 hours.

Bring the following to your transfer or new-prescription encounter:

• The original pharmacy label or prescription number from your previous state
• Your most recent A1C result and any continuous glucose monitor (CGM) data if available
• Your current total daily insulin dose and injection schedule
• Insurance card for the Nevada plan you are now using

Biosimilar basal insulins (for example, Semglee, which is interchangeable with Lantus) cannot be automatically substituted for Tresiba at the pharmacy counter unless your prescriber explicitly authorizes substitution, because insulin degludec and insulin glargine are different molecular entities, not biosimilars of each other. [18]

Manufacturer Savings and Patient Assistance Programs

Novo Nordisk offers the Tresiba $99-or-less monthly savings card for commercially insured patients not covered by federal or state government insurance. Patients who qualify pay no more than $99 per month for a 30-day Tresiba supply. [19]

Patients without any insurance may qualify for Novo Nordisk's Patient Assistance Program (PAP), which provides Tresiba at no cost to patients meeting income eligibility thresholds (generally at or below 400% of the federal poverty level). Applications are submitted through the NovoCare portal.

Nevada Medicaid non-coverage of Tresiba does not affect eligibility for the manufacturer's programs, since those programs explicitly exclude federal and state government payers. Dual-eligible patients (Medicare and Medicaid) should confirm that CMS regulations permit their use of manufacturer coupons before applying. [20]

Mark Cuban's Cost Plus Drugs (costplusdrugs.com) lists insulin degludec at a flat markup pricing model, though availability varies. Patients who pay cash should compare Cost Plus pricing with GoodRx discount cards at Nevada retail pharmacies, as the lower-cost option varies by pharmacy and package size.

What Labs Are Needed Before Starting Tresiba in Nevada

Standard pre-prescribing labs for insulin degludec include hemoglobin A1C, fasting plasma glucose, a basic metabolic panel (electrolytes, creatinine, eGFR), and a complete blood count. For type 1 diabetes, most endocrinologists also order C-peptide and islet autoantibodies (GAD-65, IA-2, ZnT8) to confirm autoimmune etiology. [5]

Renal function matters because hypoglycemia risk increases with impaired renal clearance of insulin. The FDA label notes no dose adjustment is required based on renal impairment, but providers are instructed to monitor patients more closely. [1] A creatinine and eGFR result helps the prescriber set an appropriate titration pace.

Thyroid function testing (TSH) is not required before starting degludec but is frequently obtained because hypothyroidism worsens glycemic control and is common in the type 1 diabetes population. A 2019 analysis in the Journal of Clinical Endocrinology and Metabolism (N=4,418 type 1 diabetes patients) found a 17.4% prevalence of concurrent autoimmune thyroid disease. [21]

Lipid panel results help characterize overall cardiovascular risk, relevant given the DEVOTE population data. [11] Most Nevada commercial plans and the ADA recommend a fasting lipid panel at diabetes diagnosis and every 5 years thereafter in stable patients. [3]